Guardant Infinity Biomarker Discovery
Various Solid Tumors
Development/CommercialActive
Key Facts
About Guardant Health
Guardant Health's mission is to transform cancer care by unlocking critical insights from a simple blood draw, shifting the paradigm from reactive to proactive, data-driven management. The company has achieved significant clinical adoption with over 500,000 commercial tests performed by more than 12,000 oncologists and secured FDA approval for its colorectal cancer screening test, Guardant Shield. Its strategy is built on a three-pillar business model spanning Clinical diagnostics, Biopharma solutions, and a high-growth Screening franchise, all powered by its proprietary liquid biopsy and multi-omic platform, Guardant Infinity.
View full company profileTherapeutic Areas
Other Various Solid Tumors Drugs
| Drug | Company | Phase |
|---|---|---|
| NUC-8232 | NuCana | Phase 1 |
| TCR Library Program | Medigene | Discovery |
| Cytotoxic Oncology Generic | MSN Laboratories | Pre‑clinical |
| APCEDEN® | APAC Biotech | Approved |
| Solid Tumor Profiling | Diatech Pharmacogenetics | Commercial |
| BAVENCIO (avelumab) | EMD Serono | Approved |
| FoundationOne®CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| FoundationOne®Liquid CDx Indication Expansion | Foundation Medicine | Approved/Commercial |
| 177Lu‑BetaBart (RV‑01) | AtomVie Global Radiopharma | Phase 1/2a |
| BeiGene Oncology Portfolio | EVA Pharma | Phase 2/3 |
| Bevacizumab Biosimilar | Bio Usawa Biotechnology | Preclinical |
| PRIMO‑TB161‑001 | Primo Biotechnology | Preclinical |